MyMD Pharmaceuticals Filing From Late Monday Shows Co. Entered Omnibus Waiver And Amendment Agreement With Required Holders Under Previously Announced Securities Purchase Agreement
MyMD Pharmaceuticals Filing From Late Monday Shows Co. Entered Omnibus Waiver And Amendment Agreement With Required Holders Under Previously Announced Securities Purchase Agreement
As previously disclosed, on February 21, 2023, MyMD Pharmaceuticals, Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with certain accredited investors (the "Holders") pursuant to which it agreed to sell to the Holders (i) shares of the Company's Series F Convertible Preferred Stock, with a stated value of $1,000 per share (the "Preferred Shares"), and (ii) warrants to purchase shares of the Company's common stock (the "Common Stock"), subject to adjustment (the "Warrants"). The terms of the Preferred Shares are as set forth in the Certificate of Designations filed with the Secretary of State of the State of Delaware (the "Secretary of State") as Annex C to the Company's Certificate of Incorporation (the "Certificate of Designations").
正如先前披露的那樣，2023年2月21日，myMD Pharmicals, Inc.（“公司”）與某些合格投資者（“持有人”）簽訂了證券購買協議（“購買協議”），根據該協議，該公司同意向持有人出售（i）公司F系列可轉換優先股，規定價值爲每股1,000美元的股份（“優先股”），以及（ii）購買股票的認股權證公司的普通股（“普通股”），視情況而定（“認股權證”）。優先股的條款載於作爲公司註冊證書（“指定證書”）附件C向特拉華州國務卿（“國務卿”）提交的指定證書。
On April 5, 2024, the Company entered into an Omnibus Waiver and Amendment (the "Omnibus Agreement") with the Required Holders (as defined in the Certificate of Designations). Pursuant to the Omnibus Agreement, the Required Holders agreed (i) to defer payment of the Installment Amounts (as defined in the Certificate of Designations) due on March 1, 2024, and April 1, 2024 (the "Installments"), under Section 9(a) of the Certificate of Designations, until May 1, 2024, and (ii) to waive any breach or violation of the Purchase Agreement, the Certificate of Designations, or the Warrants resulting from missing the Installments. The Company and the Required Holders further agreed pursuant to the Omnibus Agreement to amend and restate the Certificate of Designations by filing the Amended and Restated Certificate of Designations of the Series F Convertible Preferred Stock (the "Amended and Restated Certificate of Designations").
2024年4月5日，公司與所需持有人（定義見指定證書）簽訂了綜合豁免和修正案（“綜合協議”）。根據綜合協議，被要求的持有人同意（i）根據指定證書第9（a）條將2024年3月1日和2024年4月1日到期的分期付款（定義見指定證書）（“分期付款”）推遲至2024年5月1日，以及（ii）放棄任何違反或違反購買協議、指定證書或認股權證的行爲因錯過分期付款而產生的損失。根據綜合協議，公司和所需持有人進一步同意通過提交經修訂和重述的F系列可轉換優先股指定證書（“經修訂和重述的指定證書”）來修改和重申指定證書。
The Amended and Restated Certificate of Designations amends the Certificate of Designations to provide, among other things, that, except as required by applicable law, the holders of Preferred Shares will be entitled to vote with holders of the Common Stock on as as-converted basis, with the number of votes to which each holder of Preferred Shares is entitled to be calculated assuming a conversion price of $60.21 per share, which was the Minimum Price (as defined in Rule 5635 of the Rule of the Nasdaq Stock Market) applicable immediately before the execution and delivery of the Purchase Agreement, subject to certain beneficial ownership limitations as set forth in the Amended and Restated Certificate of Designations. The Amended and Restated Certificate of Designations further provides that the holders of record of the Preferred Shares, exclusively and as a separate class, shall be entitled to elect one director of the Company one time on or before June 30, 2024.
經修訂和重述的指定證書對指定證書進行了修訂，其中規定，除適用法律要求外，優先股持有人將有權在轉換後的基礎上與普通股持有人一起投票，每位優先股持有人有權獲得的選票數是假設轉換價格爲每股60.21美元，這是最低價格（定義見第5635條）執行前立即適用的納斯達克股票市場規則）以及購買協議的交付，但須遵守經修訂和重述的指定證書中規定的某些實益所有權限制。經修訂和重述的指定證書進一步規定，優先股的登記持有人，無論是單獨的還是單獨類別的，都有權在2024年6月30日當天或之前一次選舉公司的一名董事。
譯文內容由第三人軟體翻譯。